• migraine headache with or without aura

• coronary artery disease
• monoamine oxidase inhibitors

Atypical sensations:

• paresthesia

Cardiovascular:

• palpitations
• syncope
• hypertension
• hypotension

Ear, nose, and throat:

• tinnitus
• sensitivity to noise
• sinusitis
• allergic rhinitis
• upper respiratory inflammation

Gastrointestinal:

• diarrhea

Muscular:

• myalgia

Neurological:

• phonophobia
• photophobia

Respiratory:

• dyspnea

Skin:

• sweating

Miscellaneous:

• hypersensitivity

Rizatriptan (Maxalt®) is a triptan drug developed by Merck & Co. for the treatment of migraine headaches. It is available in strengths of 5 and 10 mg as tablets and orally disintegrating tablets (Maxalt-MLT).

Maxalt obtained approval by the Food and Drug Administration (FDA) on June 29, 1998. It represents a second-generation triptan.

Rizatriptan is available only by prescription in the United States and Canada.

This medication is used to treat acute migraine attacks. This drug does not prevent future migraine attacks.

External links

• Maxalt Official homepage by Merck & Co.
• Maxalt Information Fact Sheet
• Rizatriptan

Triptans | Indole compounds

Rizatriptan